成人重性抑郁障碍认知行为治疗反应的遗传学初步报告
该研究在894名重性抑郁障碍成人中,基于六种表型的基因组风险评分,探索其与认知行为治疗反应的关系。线性混合效应模型发现,仅自闭症谱系障碍基因组风险评分与MADRS-S评分变化存在显著交互作用(B=0.09,p<0.001),即该风险负荷越高,抑郁症状随时间下降越少。其他风险评分与症状严重度或变化无关。
要点
- 自闭症谱系障碍基因组风险评分越高,CBT治疗中抑郁症状下降越少(B=0.09,p<0.001)。
- 其他五种精神与认知表型的基因组风险评分与CBT疗效无关。
- 结果为初步结论,需扩大样本量并减少受试者异质性以验证。
核心结论
- 重性抑郁障碍患者对认知行为治疗的反应遗传学是复杂的,仅自闭症谱系障碍基因组风险评分与治疗中抑郁症状变化存在显著交互作用。
研究设计与样本
- 研究纳入894名在精神科环境招募的重性抑郁障碍成人,使用单核苷酸多态性基因分型阵列计算六种表型的基因组风险评分,并以线性混合效应模型检验其与认知行为治疗结局的关系。
主要发现
- 分析发现一个显著交互效应(B=0.09,p<0.001):自闭症谱系障碍基因组风险评分与MADRS-S评分变化相关,风险负荷越高,抑郁症状随时间下降越少。
- 其他精神与认知表型的基因组风险评分与抑郁症状严重度或随时间变化无关。
关键数值与推荐
- 主要结局采用Montgomery Åsberg抑郁评定量表自评版(MADRS-S)测量。
- 基因组风险评分基于六种表型的大型遗传研究计算:重性抑郁障碍、双相障碍、注意缺陷/多动障碍、自闭症谱系障碍、智力、教育程度。
临床怎么用
- 目前尚不能将基因组风险评分用于常规预测重性抑郁障碍患者对认知行为治疗的反应。
- 自闭症谱系障碍基因组风险评分可能提示CBT治疗中症状改善较少,但需进一步验证。
局限性
- 作者称结果为初步报告,强调未来需最大化样本量并限制受试者异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depressive disorder is heritable and a leading cause of disability. Cognitive behavior therapy is an effective treatment for major depression. By quantifying genetic risk scores based on common genetic variants, the aim of this report was to explore the utility of psychiatric and cognitive trait genetic risk scores, for predicting the response of 894 adults with major depressive disorder to cognitive behavior therapy. The participants were recruited in a psychiatric setting, and the primary outcome score was measured using the Montgomery Åsberg Depression Rating Scale-Self Rated. Single-nucleotide polymorphism genotyping arrays were used to calculate the genomic risk scores based on large genetic studies of six phenotypes: major depressive disorder, bipolar disorder, attention-deficit/hyperactivity disorder, autism spectrum disorder, intelligence, and educational attainment. Linear mixed-effect models were used to test the relationships between the six genetic risk scores and cognitive behavior therapy outcome. Our analyses yielded one significant interaction effect (B = 0.09, p < 0.001): the autism spectrum disorder genetic risk score correlated with Montgomery Åsberg Depression Rating Scale-Self Rated changes during treatment, and the higher the autism spectrum disorder genetic load, the less the depressive symptoms decreased over time. The genetic risk scores for the other psychiatric and cognitive traits were not related to depressive symptom severity or change over time. Our preliminary results indicated, as expected, that the genomics of the response of patients with major depression to cognitive behavior therapy were complex and that future efforts should aim to maximize sample size and limit subject heterogeneity in order to gain a better understanding of the use of genetic risk factors to predict treatment outcome.
引用
- Andersson E, Crowley JJ, Lindefors N, et al. Genetics of response to cognitive behavior therapy in adults with major depression: a preliminary report. Mol Psychiatry. 2019. PMID: 30410065. doi:10.1038/s41380-018-0289-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。